Skip to main content
Premium Trial:

Request an Annual Quote

ChanTest Acquires Applied Cell Sciences

NEW YORK (GenomeWeb News) – ChanTest today said that it has acquired Applied Cell Sciences, a Rockville, Md.-based contract research organization specializing in G-protein coupled receptors.

Cleveland-based ChanTest provides ion channel testing services and validated cell lines. The privately held firm said that it would maintain both sites and ACS' Founder and CEO Jesse Baumgold would join the company as vice president of business development and product strategy.

ACS' products will now be marketed under the ChanTest name. Among the acquired firm's products and services are optimized GPCR functional analysis tools, high-throughput screening reagents and reagent-development services, stable GPCR cell lines, cell membranes for binding studies, cryopreserved growth-arrested cells, custom cell line construction, gene-to-screen cell line construction and validation, large-scale cell cryopreservation, and specialized screening services.

ChanTest President and CEO Arthur Brown called ACS "the perfect fit." He added, "Ion channels and GPCRs are natural partners, critical and often-interrelated components of cell signaling."

Terms of the acquisition were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.